Company intelligence / Profile preview
Lukas Biomedical
New Taipei City, New Taipei City, Taiwanlukas-bio.com.tw ↗
- Ownership
- Private
- Employees
- ~88
- Development stage
- Commercial
01
Overview
Completed Phase III trials demonstrating efficacy in preventing cancer recurrence and improving overall survival. Received US FDA orphan drug designation for HCC.
- Therapeutic areas
- Oncology
- Modalities
- Autologous immune cell therapyT-cell therapiesDendritic cell therapiesNK cell therapiesNeo-antigen T cells
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
GC Cell: Strategic cooperation agreement for cell therapy development in Korea/Taiwan marketsLymphotec Inc.: Technology transfer for T-cell therapy platform
Beyond the preview
Go deeper on Lukas Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lukas Biomedical.